The announcement of promising data on the Decoy platform, especially in a prestigious setting like the AACR Annual Meeting, is likely to generate positive sentiment among investors and analysts. The detailed presentation of the data by Dr. Michael Newman, highlighting the platform's ability to activate multiple immune cell types for anti-tumor responses, supports the potential efficacy of Indaptus Therapeutics' approach to cancer treatment. This could lead to increased investor confidence and potentially a positive impact on the stock price in the short term.